AHA: Boehringer aims for 2027 survodutide submission after obesity drug passes cardio test
MH
By Maren Holt · Senior Reporter, GLP-1
Nov 9 09:45 ETSource: Fierce Biotech
From the source
Read at fiercebiotech.comAHA: Boehringer aims for 2027 survodutide submission after obesity drug passes cardio test
